Table 3 Primary and secondary outcome metrics.

From: A randomized controlled trial of alpha phase-locked auditory stimulation to treat symptoms of sleep onset insomnia

Variable

Effect of condition (p-value)

Effect of recording night (p-value)

Effect of week (p-value)

Effect of weeknight (p-value)

Stimulation—Sham across-night Mean ± SD (p-value)

EEG estimated SOL (minutes)

 − 9.62 (0.0019)

F(3,112.46) = 0.6212 (0.6027)

F(1,114.77) = 0.0136 (0.9074)

F(6,114.03) = 1.2178 (0.3023)

− 10.5 ± 15.9 (0.0032**)

EEG estimated SOL variability

− 9.60 ± 13.9 (0.00096***)

Actigraphy estimated SOL (minutes)

− 7.88 (0.0156)

F(3,133.57) = 0.3396 (0.7967)

− 5.66 (0.0282*)Week 1—Week 2

F(6,139.54) = 0.5112 (0.7991)

− 6.05 ± 1.30 (0.0224*)

Actigraphy estimated SOL variability

− 5.75 ± 11.0 (0.0280*)

Actigraphy estimated TST (hours)

F(1,138.04) = 0.5352 (0.4657)

F(3,136.04) = 1.2157 (0.3065)

F(1,138.15) = 0.0951 (0.7583)

F(6,135.38) = 0.6098 (0.7221)

 

Actigraphy estimated Eff (%)

3.04 (0.0034*)

F(3,135.97) = 0.1544 (0.9267)

F(1,138.11) = 2.2642 (0.1347)

F(6,135.87) = 0.6652 (0.6779)

 

Actigraphy estimated WASO (minutes)

F(1,138.02) = 1.3748 (0.2430)

F(3,136.02) = 0.3605 (0.7816)

F(1,138.07) = 0.1885 (0.6649)

F(6,134.09) = 1.5546 (0.1653)

 

Actigraphy estimated nWASO

F(1,138.03) = 0.4378 (0.5093)

F(3,136.03) = 0.4955 (0.6860)

F(1,138.08) = 0.1399 (0.7089)

F(1,134.15) = 0.6004 (0.7296)

 

Subjective SOL (minutes)

F(1,141.35) = 1.5989 (0.2081)

F(3,139.24) = 2.4328 (0.0676)

F(1,141.44) = 0.1474 (0.7016)

F(6,138.1) = 1.5463 (0.1676)

 

Subjective TST (hours)

F(1,140.84) = 0.0254 (0.8737)

F(3,138.69) = 0.3136 (0.8155)

F(1,140.97) = 0.0332 (0.8557)

F(6,138.35) = 0.4705 (0.8293

 

Subjective WASO (minutes)

F(1,140.52) = 2.3208 (0.1299)

F(3,138.26) = 1.525 (0.2108)

− 10.2 (0.0045) Week 1–Week2

F(6,140.28) = 0.7253 (0.6299)

 

Subjective Sleep Quality

χ2(4,n = 131) = 6.4486 (0.1681)

χ2(12,n = 131) = 10.6587 (0.5584)

χ2(4,n = 131) = 2.3867 (0.6650)

χ2(20,n = 131) = 13.2261 (0.8675)